School of Medicine
Showing 251-290 of 290 Results
-
Gabriel Velez, MD, PhD
Resident in Ophthalmology
Current Role at StanfordResident Physician
-
Douglas Vollrath
Professor of Genetics and, by courtesy, of Ophthalmology
Current Research and Scholarly InterestsThe Vollrath lab works to uncover molecular mechanisms relevant to the health and pathology of the outer retina. We study metabolic and other cellular interactions between the glial-like retinal pigment epithelium (RPE) and adjacent photoreceptors, with the goals of understanding the pathogenesis of photoreceptor degenerative diseases such as age-related macular degeneration and retinitis pigmentosa, and developing therapies.
-
Brian A. Wandell
Isaac and Madeline Stein Family Professor and Professor, by courtesy, of Electrical Engineering, of Ophthalmology and at the Graduate School of Education
Current Research and Scholarly InterestsModels and measures of the human visual system. The brain pathways essential for reading development. Diffusion tensor imaging, functional magnetic resonance imaging and computational modeling of visual perception and brain processes. Image systems simulations of optics and sensors and image processing. Data and computation management for reproducible research.
-
Sophia Y. Wang, MD, MS
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsI use and integrate a wide variety of data sources in my research, spanning both structured and unstructured forms, including national survey datasets, health insurance claims data, patient generated online text, surgical video, and electronic health records. I investigate outcomes of treatments for glaucoma and cataract, as well as other areas of ophthalmology. My focus is on developing artificial intelligence methods to predict ophthalmology outcomes.
-
Sui Wang, PhD
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.
1. Investigating retinal development:
We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.
2. Understanding diabetes-induced cell-type-specific responses in the retina:
Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.
3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo. -
Rain Runxia Wen
Postdoctoral Scholar, Ophthalmology
BioRain Runxia Wen obtained her B.Sc. (Hons) in biology in 2012, and her Ph.D. degree in cell and developmental biology in 2018. She joined the Goldberg Lab in the Department of Ophthalmology at Stanford University in 2019. She is currently developing epigenetic tools to promote neuroregeneration, especially retinal ganglion cell, and optic nerve regeneration.
-
Julian Wolf MD, MS
Postdoctoral Scholar, Ophthalmology
BioDr. Julian Wolf M.D., M.S. is a clinician-scientist, ophthalmologist, and postdoctoral fellow in the Department of Ophthalmology, Stanford University. Dr. Wolf engages in translational research with the goal of finding new therapies for blinding eye diseases, including age-related macular degeneration and diabetic retinopathy. His interests include combining cutting-edge omics technology, systems biology, and artificial intelligence to assess the mechanisms of aging and disease of the human eye that he validates in animal and in vitro models.
Dr. Wolf graduated medical school in Germany and started his ophthalmology residency training at the University of Freiburg, where he was awarded the Henning Zügel Foundation Award for excellence in research. He identified a new therapeutic target for neovascular age-related macular degeneration and developed a web resource (https://www.eye-transcriptome.com) that allows scientists to explore his data covering gene expression profiles of human eye diseases. For his work, he was awarded the prestigious Helmholtz Research Award of the German Society of Ophthalmology.
As a postdoctoral fellow in the Department of Ophthalmology at Stanford University, Dr. Wolf developed computational methods that integrate liquid biopsy proteomics, single cell transcriptomics, and artificial intelligence to investigate aging and disease mechanisms at the cell level in living patients (Wolf et al., Cell, 2023). For his work, he was awarded the Research Award of the VitreoRetinal Surgery Foundation. Dr. Wolf graduated with a Master of Science in Translational Research and Applied Medicine from Stanford University. Together with world-class scientists, industry leaders, and successful entrepreneurs, he developed strategies how his scientific discoveries in the laboratory could one day improve his patients' lives.
Dr. Wolf has published 38 peer-reviewed manuscripts, among them first-authorships in Cell, BBA Molecular Basis of Disease, and Genomics. -
Albert Y. Wu, MD, PhD, FACS
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsMy translational research focuses on using autologous stem cells to recreate a patient’s ocular tissues for potential transplantation. We are generating tissue from induced pluripotent stem cells to treat limbal stem cell deficiency in patients who are bilaterally blind. By applying my background in molecular and cellular biology, stem cell biology, oculoplastic surgery, I hope to make regenerative medicine a reality for those suffering from orbital and ocular disease.
-
George Yang
Postdoctoral Scholar, Ophthalmology
BioGeorge Ming YANG is a 2nd-year Postdoc scholar at Stanford Ophthalmology. He obtained his Ph.D. in Ophthalmology in 2022 at Li Ka Shing Faculty of Medicine, The University of Hong Kong. Before that, he got a Bachelor of Clinical Medicine (B.Med) in the Department of Clinical Medicine, at Taishan Medical University (currently Shandong First Medical University & Shandong Academy of Medical Sciences), China, in 2017.
Under the guidance of Prof. Wai Ching Lam, Prof. Kwok-Fai So, and Dr.Amy Lo, he mainly focuses on the mechanism studies and investigation of potential therapeutic targets of age-related macular degeneration and retinal degeneration in vitro and in vivo at Li Ka Shing Faculty of Medicine, The University of Hong Kong.
His research interests and projects also extend to pharmaceutical and screening of the neuroprotection and optic nerve regeneration strategies in glaucoma under Dr.Yang Hu's supervision. He also has been leading a SPARK Program in Translational Research at Stanford University to promote Coph-NMNAT2 gene therapy into clinical use.
He has published 18 peer-reviewed articles as a first/co-first author in such journals, with 4 on-going projects in his postdoctoral study. He has been a peer reviewer for 22 journals including The Lancet Regional Health-Western Pacific, Theranostics, Cell & Bioscience, Journal of Clinical Medicine, and Stem Cell Research & Therapy. His study was funded by the National Student’s Platform for Innovation and Entrepreneurship Training Program (No.201510439107).
In addition to his research, he has been serving as a guest journal editor for 3 journals, including Frontiers in Cell and Developmental Biology, Biomedicines, and Cell Transplantation while pursuing his Ph.D. and Postdoctoral studies.
His research is recognized by the field and he was awarded the National Scholarship of China (Top 0.5%), the National Endeavor Scholarship of China (Top 1%), the Outstanding Graduate Award (Undergraduate GPA ranking 1/50 in class and 36/827 in the department of clinical medicine), Postgraduate Scholarship for MPhil and PhD studies, YS and Christabel Lung Postgraduate Scholarship, Mary Sun Medical Scholarship (Two most preeminent MPhil/Ph.D. students in the Li Ka Shing Faculty of Medicine awarded).
He is dedicated to coaching high-performance teams & and individuals. He has been a program leader for the Stanford Graduate Summer Research Program and mentored 7 postgraduates. He has been a research mentor at Stanford Ophthalmology for two years and mentored high school, college, and PhD students from domestically and overseas. Additionally, he is a sports fan with a Stanford Intramural Championship (Boat Racing). He enjoys the sport's passion and team spirit as a captain. -
Shuai Yang
Postdoctoral Scholar, Ophthalmology
BioDr. Yang obtained doctorate degree in Ophthalmology at 2017 in Tongji University, Shanghai, China. Afterwards, He works as an eye doctor in Shanghai Tenth People's Hospital. His clinial and experimantal interest is retinal disease. In June 2023, he joined Prof. Hartnett's lab to conduct postdoctoral research in neovascularization-related retinal diseases.
-
Charles Yu MD
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsCorneal opacity is a leading cause of blindness. Cornea transplantation is at high risk of rejection when there is pre-existing vascularization of the cornea and in pediatric patients. Cornea transplant shortage remains a worldwide problem with millions on waitlists. Our laboratory is developing multiple strategies for treatment of corneal blindness. We are testing advanced materials and designs for keratoprostheses with the goal of reducing complications and easing surgical implantation. We are also developing intraocular electronic display prostheses for bypassing cornea opacity, a novel strategy that could allow for high quality vision without corneal clarity.
